A confirmatory Phase 3 registrational trial of Linsitinib
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Linsitinib (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- 20 Jan 2025 New trial record
- 14 Jan 2025 According to Sling Therapeutics media release, the company is on track to initiate our confirmatory Phase 3 registrational trial later this year